Monthly
US$200
Billed every month
Sign in to subscribeBromhexine Hydrochloride Injection
As of 13 November 2026, for Bromhexine Hydrochloride Injection, 8 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 29 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders29View records ↓
Under-review filings8View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers27View records ↓
API companies with A status19View records ↓
Chemical-drug catalogue
Loaded records: 29 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 26 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Duo Duo Pharma Co., Ltd. romanized | Duo Duo Pharma Co., Ltd. romanized | 国药准字H20265904 | 2026/09/08 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Fu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanized | Fu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20265301 | 2026/07/21 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Zhong Yu Pharmaceutical (Haikou) Co., Ltd. romanized | Zhong Yu Pharmaceutical (Haikou) Co., Ltd. romanized | 国药准字H20264521 | 2026/05/27 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Xian Da Mo Pharmaceutical Co., Ltd. romanized | Shaanxi Bo Sen Biopharmaceutical Shareholding Group Co., Ltd. romanized | 国药准字H20264263 | 2026/05/07 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Ta He Shi Hui Chuang Pharmaceuticals Co., Ltd. romanized | Yu Song Yuan Pharma Co., Ltd. romanized | 国药准字H20263902 | 2026/05/06 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yi Ling Wan Zhou International Pharmaceutical Co., Ltd. romanized | Jewim Pharmaceutical (Shandong) Co., Ltd. | 国药准字H20264056 | 2026/04/21 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | Shanghai Xian Dai Ha Sen (Shang Qiu) Pharma Co., Ltd. romanized | 国药准字H20263734 | 2026/03/25 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hebei Hui De Xu Sheng Pharmaceuticals Technology Co., Ltd. romanized | Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | 国药准字H20263026 | 2026/01/05 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shaanxi Bo Sen Biopharmaceutical Shareholding Group Co., Ltd. romanized | Shaanxi Bo Sen Biopharmaceutical Shareholding Group Co., Ltd. romanized | 国药准字H20256398 | 2025/12/22 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | Chu Xiong He Chuang Pharma Co., Ltd. romanized | 国药准字H20255923 | 2025/11/12 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Quan Xing Pharmaceutical Co., Ltd. romanized | Hainan Quan Xing Pharmaceutical Co., Ltd. romanized | 国药准字H20255538 | 2025/09/16 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| CISEN PHARMACEUTICAL CO., LTD. | CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20255075 | 2025/07/30 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| E Mei Shan Tong Hui Pharmaceutical Co., Ltd. romanized | E Mei Shan Tong Hui Pharmaceutical Co., Ltd. romanized | 国药准字H20255022 | 2025/07/29 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Anhui Xin Shi Ji Pharma Co., Ltd. romanized | Ping Guang Pharmaceutical Co., Ltd. romanized | 国药准字H20254535 | 2025/06/10 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | 国药准字H20057396 | 2024/10/16 | 2ml:4mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Hubei Jin Yao Pharma Co., Ltd. romanized | Hubei Jin Yao Pharma Co., Ltd. romanized | 国药准字H20244991 | 2024/09/26 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Heilongjiang Zhen Bao Dao Pharma Co., Ltd. romanized | Heilongjiang Zhen Bao Dao Pharma Co., Ltd. romanized | 国药准字H20244392 | 2024/07/09 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Huluwa Pharmaceutical Group Co., Ltd. | Hainan Huluwa Pharmaceutical Group Co., Ltd. | 国药准字H20243551 | 2024/04/24 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H20234640 | 2023/12/13 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jilin Si Zhang Pharmaceutical Co., Ltd. romanized | Jilin Si Zhang Pharmaceutical Co., Ltd. romanized | 国药准字H20234075 | 2023/08/29 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Zheng Da Qing Jiang Pharmaceutical Co., Ltd. romanized | Jiangsu Zheng Da Qing Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H20233628 | 2023/05/29 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Wan Bang De Pharmaceutical Group Co., Ltd. romanized | Wan Bang De Pharmaceutical Group Co., Ltd. romanized | 国药准字H20223868 | 2022/11/22 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Beijing Shi Xin Li Cheng Pharmaceuticals Technology Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20223720 | 2022/10/11 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H31022703 | 2021/09/18 | 2ml：4mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Guangzhou Yi Pin Hong Pharmaceutical Co., Ltd. romanized | Hebei Kai Wei Pharmaceutical Co., Ltd. romanized | 国药准字H20213726 | 2021/09/13 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangxi Yi You Pharma Co., Ltd. romanized | Jiangxi Yin Tao Pharma Co., Ltd. romanized | 国药准字Ｈ20213658 | 2021/08/25 | 2ml：4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | 国药准字H20183123 | 2021/07/30 | 2ml：4mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20213214 | 2021/03/23 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Giantech Hi-technology Development Co., Ltd. | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20213154 | 2021/03/02 | 2ml:4mg | Generic approved under the new chemical-drug registration classification | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 27 distinct approval numbers and 27 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Hua Run Shuang He Pharma Co., Ltd. romanized | 国药准字H11022093 | 2ml:4mg | Category B | XR05CBX169B002010100144 | NHSA |
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20256018 | 2ml:4mg | Category B | XR05CBX169B002010100148 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H31022703 | 2ml:4mg | Category B | XR05CBX169B002010100808 | NHSA |
| Jiangsu Zheng Da Qing Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H20233628 | 2ml:4mg | Category B | XR05CBX169B002010101522 | NHSA |
| Hubei Jin Yao Pharma Co., Ltd. romanized | 国药准字H20244991 | 2ml:4mg | Category B | XR05CBX169B002010101866 | NHSA |
| Zai Wei Pharma (Hainan) Co., Ltd. romanized | 国药准字H20223720 | 2ml:4mg | Category B | XR05CBX169B002010102068 | NHSA |
| E Mei Shan Tong Hui Pharmaceutical Co., Ltd. romanized | 国药准字H20255022 | 2ml:4mg | Category B | XR05CBX169B002010102092 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20213154 | 2ml:4mg | Category B | XR05CBX169B002010102189 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20213214 | 2ml:4mg | Category B | XR05CBX169B002010102763 | NHSA |
| Guangzhou Yi Pin Hong Pharmaceutical Co., Ltd. romanized | 国药准字H20213726 | 2ml:4mg | Category B | XR05CBX169B002010102829 | NHSA |
| Shanghai Xian Dai Ha Sen (Shang Qiu) Pharma Co., Ltd. romanized | 国药准字H20263734 | 2ml:4mg | Category B | XR05CBX169B002010103081 | NHSA |
| Jilin Si Zhang Pharmaceutical Co., Ltd. romanized | 国药准字H20234075 | 2ml:4mg | Category B | XR05CBX169B002010103282 | NHSA |
| Heilongjiang Zhen Bao Dao Pharma Co., Ltd. romanized | 国药准字H20244392 | 2ml:4mg | Category B | XR05CBX169B002010103783 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20255075 | 2ml:4mg | Category B | XR05CBX169B002010104127 | NHSA |
| Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | 国药准字H20057396 | 2ml:4mg | Category B | XR05CBX169B002010104207 | NHSA |
| Anhui Xin Shi Ji Pharma Co., Ltd. romanized | 国药准字H20254535 | 2ml:4mg | Category B | XR05CBX169B002010104360 | NHSA |
| Fu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20265301 | 2ml:4mg | Category B | XR05CBX169B002010104561 | NHSA |
| Wan Bang De Pharmaceutical Group Co., Ltd. romanized | 国药准字H20223868 | 2ml:4mg | Category B | XR05CBX169B002010104723 | NHSA |
| Jiangxi Yi You Pharma Co., Ltd. romanized | 国药准字H20213658 | 2ml:4mg | Category B | XR05CBX169B002010105381 | NHSA |
| Hainan Quan Xing Pharmaceutical Co., Ltd. romanized | 国药准字H20255538 | 2ml:4mg | Category B | XR05CBX169B002010105765 | NHSA |
| Hainan Huluwa Pharmaceutical Group Co., Ltd. | 国药准字H20243551 | 2ml:4mg | Category B | XR05CBX169B002010105789 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20183123 | 2ml:4mg | Category B | XR05CBX169B002010110349 | NHSA |
| Zhong Yu Pharmaceutical (Haikou) Co., Ltd. romanized | 国药准字H20264521 | 2ml:4mg | Category B | XR05CBX169B002010183237 | NHSA |
| Xian Da Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20264263 | 2ml:4mg | Category B | XR05CBX169B002010183239 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20234640 | 2ml:4mg | Category B | XR05CBX169B002010183719 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20255923 | 2ml:4mg | Category B | XR05CBX169B002010184547 | NHSA |
| Hebei Hui De Xu Sheng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263026 | 2ml:4mg | Category B | XR05CBX169B002010184987 | NHSA |
| Hua Run Shuang He Pharma Co., Ltd. romanized | 国药准字H11022093 | 2ml:4mg | Category B | XR05CBX169B002010200144 | NHSA |
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20256018 | 2ml:4mg | Category B | XR05CBX169B002010200148 | NHSA |
| Jiangsu Zheng Da Qing Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H20233628 | 2ml:4mg | Category B | XR05CBX169B002010201522 | NHSA |
| Hubei Jin Yao Pharma Co., Ltd. romanized | 国药准字H20244991 | 2ml:4mg | Category B | XR05CBX169B002010201866 | NHSA |
| Zai Wei Pharma (Hainan) Co., Ltd. romanized | 国药准字H20223720 | 2ml:4mg | Category B | XR05CBX169B002010202068 | NHSA |
| E Mei Shan Tong Hui Pharmaceutical Co., Ltd. romanized | 国药准字H20255022 | 2ml:4mg | Category B | XR05CBX169B002010202092 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20213154 | 2ml:4mg | Category B | XR05CBX169B002010202189 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20213214 | 2ml:4mg | Category B | XR05CBX169B002010202763 | NHSA |
| Guangzhou Yi Pin Hong Pharmaceutical Co., Ltd. romanized | 国药准字H20213726 | 2ml:4mg | Category B | XR05CBX169B002010202829 | NHSA |
| Jilin Si Zhang Pharmaceutical Co., Ltd. romanized | 国药准字H20234075 | 2ml:4mg | Category B | XR05CBX169B002010203282 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20255075 | 2ml:4mg | Category B | XR05CBX169B002010204127 | NHSA |
| Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | 国药准字H20057396 | 2ml:4mg | Category B | XR05CBX169B002010204207 | NHSA |
| Anhui Xin Shi Ji Pharma Co., Ltd. romanized | 国药准字H20254535 | 2ml:4mg | Category B | XR05CBX169B002010204360 | NHSA |
| Fu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20265301 | 2ml:4mg | Category B | XR05CBX169B002010204561 | NHSA |
| Wan Bang De Pharmaceutical Group Co., Ltd. romanized | 国药准字H20223868 | 2ml:4mg | Category B | XR05CBX169B002010204723 | NHSA |
| Jiangxi Yi You Pharma Co., Ltd. romanized | 国药准字H20213658 | 2ml:4mg | Category B | XR05CBX169B002010205381 | NHSA |
| Hainan Quan Xing Pharmaceutical Co., Ltd. romanized | 国药准字H20255538 | 2ml:4mg | Category B | XR05CBX169B002010205765 | NHSA |
| Hainan Huluwa Pharmaceutical Group Co., Ltd. | 国药准字H20243551 | 2ml:4mg | Category B | XR05CBX169B002010205789 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20183123 | 2ml:4mg | Category B | XR05CBX169B002010210349 | NHSA |
| Xian Da Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20264263 | 2ml:4mg | Category B | XR05CBX169B002010283239 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20234640 | 2ml:4mg | Category B | XR05CBX169B002010283719 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20255923 | 2ml:4mg | Category B | XR05CBX169B002010284547 | NHSA |
| Hebei Hui De Xu Sheng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263026 | 2ml:4mg | Category B | XR05CBX169B002010284987 | NHSA |
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20256018 | 2ml:4mg | Category B | XR05CBX169B002010300148 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20213154 | 2ml:4mg | Category B | XR05CBX169B002010302189 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20213214 | 2ml:4mg | Category B | XR05CBX169B002010302763 | NHSA |
| Jiangxi Yi You Pharma Co., Ltd. romanized | 国药准字H20213658 | 2ml:4mg | Category B | XR05CBX169B002010305381 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20234640 | 2ml:4mg | Category B | XR05CBX169B002010383719 | NHSA |
| Hebei Hui De Xu Sheng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263026 | 2ml:4mg | Category B | XR05CBX169B002010384987 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H31022703 | 2ml:4mg | Category B | XR05CBX169B002020100808 | NHSA |
| Zhong Yu Pharmaceutical (Haikou) Co., Ltd. romanized | 国药准字H20264521 | 2ml:4mg | Category B | XR05CBX169B002020183237 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 8 filings and 8 distinct first applicants.
Generic 6 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Shandong Qidu Pharmaceutical Co., Ltd. | CYHS2602137 | Generic | 2026/08/27 | Not stated by source | CDE |
| Hubei Jin Yao Pharma Co., Ltd. romanized | CYHB2601083 | Supplement | 2026/06/10 | Not stated by source | CDE |
| Hubei Mei Lin Pharma Co., Ltd. romanized | CYHB2600858 | Supplement | 2026/05/01 | Not stated by source | CDE |
| Henan Pu Rui Pharma Co., Ltd. romanized | CYHS2600830 | Generic | 2026/04/10 | Not stated by source | CDE |
| Chengdu Hua Yu Pharmaceutical Co., Ltd. romanized | CYHS2502423 | Generic | 2025/07/08 | Not stated by source | CDE |
| Hubei Wu Shi Pharma Co., Ltd. romanized | CYHS2501654 | Generic | 2025/05/08 | Not stated by source | CDE |
| YaoPharma Co., Ltd. | CYHS2500847 | Generic | 2025/02/26 | Not stated by source | CDE |
| Hubei Min Kang Pharma Group Co., Ltd. romanized; Hubei Mei Lin Pharma Co., Ltd. romanized | CYHS2500834 | Generic | 2025/02/25 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Shandong Qidu Pharmaceutical Co., Ltd. | CYHS2602137 | Generic | 2026/08/27 | Not stated by source | CDE |
| Henan Pu Rui Pharma Co., Ltd. romanized | CYHS2600830 | Generic | 2026/04/10 | Not stated by source | CDE |
API registrations
Non-component matches: 19 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸溴己新 · No verified English name | Hubei Mei Lin Pharma Co., Ltd. romanized | Y20240001175 | A | Exact ingredient | 2026/08/13 | CDE |
| 盐酸溴己新 · No verified English name | Yao Kang Zhong Tuo (Jiangsu) Pharmaceuticals Technology Co., Ltd. romanized | Y20240001095 | I | Exact ingredient | 2026/01/08 | CDE |
| 盐酸溴己新 · No verified English name | Hubei Wu Shi Pharma Co., Ltd. romanized | Y20230000895 | A | Exact ingredient | 2026/09/16 | CDE |
| 盐酸溴己新 · No verified English name | Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | Y20230000613 | A | Exact ingredient | 2026/01/23 | CDE |
| 盐酸溴己新 · No verified English name | Shandong Qidu Pharmaceutical Co., Ltd. | Y20230000542 | A | Exact ingredient | 2025/12/03 | CDE |
| 盐酸溴己新 · No verified English name | Wu Yi Ci Hang Pharma Co., Ltd. romanized | Y20220000824 | A | Exact ingredient | 2025/09/24 | CDE |
| 盐酸溴己新 · No verified English name | Chengdu Xin Heng Chuang Pharma Co., Ltd. romanized | Y20220000708 | A | Exact ingredient | 2026/01/22 | CDE |
| 盐酸溴己新 · No verified English name | VEN PETROCHEM & PHARMA (INDIA) PVT LTD. | Y20210000882 | A | Exact ingredient | 2024/07/26 | CDE |
| 盐酸溴己新 · No verified English name | Jiangxi Bo Ya Xin He Pharmaceutical Co., Ltd. romanized | Y20200000365 | A | Exact ingredient | 2026/05/06 | CDE |
| 盐酸溴己新 · No verified English name | Shanghai Xu Dong Hai Pu Nan Tong Pharma Co., Ltd. romanized | Y20190021429 | A | Exact ingredient | 2026/03/21 | CDE |
| 盐酸溴己新 · No verified English name | Guangzhou Yi Pin Hong Pharmaceutical Co., Ltd. romanized | Y20190000846 | A | Exact ingredient | 2026/07/31 | CDE |
| 盐酸溴己新 · No verified English name | Hunan Er Kang Pharmaceutical Co., Ltd. romanized | Y20190008448 | A | Exact ingredient | 2025/02/08 | CDE |
| 盐酸溴己新 · No verified English name | Jiangxi Yi You Pharma Co., Ltd. romanized | Y20190008344 | A | Exact ingredient | 2024/06/04 | CDE |
| 盐酸溴己新 · No verified English name | Tai Cang Pharmaceutical Factory romanized | Y20190007187 | A | Exact ingredient | 2024/03/29 | CDE |
| 盐酸溴己新 · No verified English name | Zhejiang Le Pu Pharma Co., Ltd. romanized | Y20190004465 | A | Exact ingredient | 2025/05/01 | CDE |
| 盐酸溴己新 · No verified English name | Hua Run Shuang He Pharma Co., Ltd. romanized | Y20190003977 | A | Exact ingredient | — | CDE |
| 盐酸溴己新 · No verified English name | Wan Bang De Pharmaceutical Group Co., Ltd. romanized | Y20190003549 | A | Exact ingredient | 2025/06/19 | CDE |
| 盐酸溴己新 · No verified English name | Chengdu Xin Heng Chuang Pharma Co., Ltd. romanized | Y20180001038 | A | Exact ingredient | 2026/01/09 | CDE |
| 盐酸溴己新 · No verified English name | Jiangsu Run An Pharmaceutical Co., Ltd. romanized | Y20170001511 | A | Exact ingredient | 2026/09/12 | CDE |
| 盐酸溴己新 · No verified English name | Hebei Chuang Jian Pharma Co., Ltd. romanized | Y20170000639 | A | Exact ingredient | 2024/02/23 | CDE |
| 盐酸溴己新 · No verified English name | BIDACHEM SPA | Y20170000561 | I | Exact ingredient | — | CDE |
| 盐酸溴己新 · No verified English name | Hebei Guo Long Pharmaceutical Co., Ltd. romanized | Y20170000261 | A | Exact ingredient | 2023/07/02 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/08/27Accepted
Shandong Qidu Pharmaceutical Co., Ltd.
CYHS2602137
Fact date: 2026/08/27 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Bromhexine Hydrochloride Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy